Aclaris Therapeutics reported a quarterly loss of $0.15 per share, slightly better than the Zacks Consensus Estimate loss of $0.16. The loss narrowed from $0.13 per share a year ago, indicating mixed year-over-year performance but a modest earnings-result beat versus expectations.
Aclaris Therapeutics reported a quarterly loss of $0.15 per share, slightly better than the Zacks Consensus Estimate loss of $0.16. The loss narrowed from $0.13 per share a year ago, indicating mixed year-over-year performance but a modest earnings-result beat versus expectations.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.10
Ticker Sentiment
